Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
61 participants
INTERVENTIONAL
2007-03-31
2007-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
3 weeks of Montelukast and 3 weeks of placebo treatment
montelukast
10 mg montelukast tablet each evening for 3 weeks or placebo for 3 weeks in cross-over manner
2
3 weeks of placebo and 3 weeks of montelukast treatment
montelukast
10 mg montelukast tablet each evening for 3 weeks or placebo for 3 weeks in cross-over manner
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
montelukast
10 mg montelukast tablet each evening for 3 weeks or placebo for 3 weeks in cross-over manner
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Allergic symptoms in both upper airways (allergic rhinitis) and lower airways (asthma-like symptoms or diagnosed asthma) and at least one of the following:
* Allergic conjunctivitis
* Atopic eczema
* Oral symptoms from vegetables or fruits by cross reactivity to birch
* Urticaria in allergen exposure
Exclusion Criteria
* Current smoking
* Other major disease or need for regular drug treatment
* Pregnancy
18 Years
40 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Merck Sharp & Dohme LLC
INDUSTRY
University of Helsinki
OTHER
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Tari Haahtela, Professor
Role: PRINCIPAL_INVESTIGATOR
Skin and Allergy Hospital, Helsinki University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Skin and Allergy Hospital, Helsinki University Hospital
Helsinki, , Finland
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Lehtimaki L, Petays T, Haahtela T. Montelukast is not effective in controlling allergic symptoms outside the airways: a randomised double-blind placebo-controlled crossover study. Int Arch Allergy Immunol. 2009;149(2):150-3. doi: 10.1159/000189198. Epub 2009 Jan 6.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HUS7/E5/07
Identifier Type: -
Identifier Source: org_study_id